mon malignant abnormality was prostatic adenocarcinoma identified in 10 (8.6%) BRCA1 carriers , and 3 (3.8%) BRCA2 carriers (Figure, A). Initial screening identified malignant abnormalities of the prostate (n = 9), pancreas (n = 2), and skin (n = 2), all treated with a curative intent.
Discussion | Current recommendations for the screening of BRCA-positive men include annual clinical breast examination starting at age 35 and yearly prostate cancer screening in BRCA2 carriers starting at age 45. 5 We devised a screening protocol for male BRCA mutation carriers based on malignant abnormalities previously associated with this group of patients. Twenty-eight percent of malignant abnormalities were identified during screening, all of which were found at early stage and amenable to curative treatment. In this study, overall cancer incidence among BRCA carriers was higher than that of the general population. Detection rates of prostate cancer were similar to those in the IMPACT study. 6 The rate of prostate cancer among BRCA1
carriers was more than twice as high (8.6% vs 3.8%), likely owing to the high prevalence of the Jewish founder mutation 185delAG in this population. Melanoma was the second most common malignant abnormality, related to the high incidence of melanoma in the Israeli population. We used abdominal ultrasound and CA19-9 testing to screen for pancreatic cancer and identified 2 cases of malignant disease, both received definitive local surgical treatment, emphasizing the profound clinical impact screening may have on patient outcome.
Limitations. Limitations of the study include initial screening ascertainment bias, and lack of control group to establish the benefit of screening.
Conclusion | Our initial findings suggest that in addition to screening for prostate and breast cancer, as recommended in current guidelines, there may be a role for screening for pancreatic cancer and melanoma, whereas screening for colon cancer may not be justified. Further long-term studies are needed to determine the effect of screening on mortality. 
Evaluating Treatment Effect Based on Duration of Response for a Comparative Oncology Study
Quantitative procedures for analyzing data for progressionfree survival (PFS) and overall survival are generally well established. However, it is not clear how to analyze data efficiently for duration of response (DOR), a clinically important end point that is related to quality of life and is endorsed by regulatory agencies for drug evaluation.
1,2 Duration of response is the time from response (R) to progression/death (P/D). The existing statistical procedures for DOR are valid when certain model assumptions are correctly specified. 3 Therefore, in a typical report of a clinical study, DOR is summarized descriptively. Moreover, the Kaplan-Meier curves (KMCs) to estimate the distribution of DOR are generally based on observations from responders and may be biased owing to dependent censoring. 2 Here, we present a simple, intuitive procedure to estimate mean DOR in a time window for which KMCs for PFS are well defined. We illustrate this method with data from a clinical trial, PROFILE-1014, to evaluate crizotinib vs chemotherapy for patients with ALKpositive lung cancer. 4 Method | In Figure 1A , we present KMCs of PFS. The PFS was significantly longer with crizotinib than with chemotherapy (F, 0.45; 95% CI, 0.35-0.60; P < .001). Furthermore, the objective response rates for crizotinib and chemotherapy were 74% and 45%, respectively. Because there is little information regarding PFS beyond month 30 for either arm, we analyzed data by month 30. When a PFS time is not censored before month 30, possible patterns of time to R and P/D and the corresponding DORs are shown in Figure 2 . For case 1, R and P/D occurred at month 3 and month 12, and the DOR was 9 months. For case 2, R occurred at month 9 and the patient was P/D-free at month 30, DOR before month 30 was 21 months. For cases 3 and 4, patients did not respond during the study, therefore, DOR was 0. In general, if we let P/D/R be a composite endpoint (ie, first of progression, death, or response), DOR is PFS time minus P/D/R eventfree time and its mean can be estimated over 30 months accordingly.
Results | For crizotinib, the restricted mean PFS time up to month 30 was the area under the KMC for PFS in Figure 1B . Likewise, the counterpart for P/D/R-free was the area under the KMC in Figure 1C . This simple estimation procedure for restricted mean event-free time has been discussed extensively. 5, 6 The restricted mean DOR for crizotinib was therefore the area between 2 KMC's in Figure 1D , which was 10.4 months. That is, on average, future patients treated by crizotinib would have 10.4-month DOR over a 30-month followup. The corresponding DOR for chemotherapy would be 3.0 months. Over 30-month follow-up, the mean difference of DOR was 7.4 months (95% CI, 6.0-8.8 months; P < .001). This result, coupled with the mean DOR of 3.0 months for chemotherapy as reference, provides clinically interpretable treatment effect for crizotinib.
Discussion | The DOR, which collectively uses information from R and P/D, is underused in practice partly owing to lack of a reliable estimation procedure that does not require strong modeling assumptions. If we compare DOR times between crizotinib and chemotherapy among responders, owing to the higher objective response rate in the crizotinib arm, it would undermine the treatment benefit with respect to DOR. A caveat for our proposal is that mean DOR depends on a specific time window that can be preselected based on clinical consideration. Empirically one may choose the largest possible time window beyond which a small proportion of patients (eg, 2%) remain at risk for P/D. Like other procedures such as hazard ratio estimation, this time window constraint may not be avoidable without a parametric model for extrapolation. Lastly, it can be quite informative to examine the temporal treatment effect profile by choosing several time windows to estimate restricted mean differences in DOR.
